
CLAIMS


1. Use of an effective amount of a combination of:


at least one therapeutic agent selected from the group consisting of a bromodomain, an extra-terminal protein inhibitor, an anti-CD20 monoclonal antibody, and a BCL2 inhibitor; and

a compound having a structure of Formula (I):



(I)

or a stereoisomer, a pharmaceutically acceptable salt, or solvate thereof, wherein R_1, R_2, R_3, and R_4 are independently selected from the group consisting of H, Cl, -CN and $-CF_3$; wherein A is selected from the group consisting of H and C_{1-6} alkyl; wherein D is selected from the group consisting of -OH and $-O(C_{1-6}$ alkyl); wherein R_5 and R_6 are independently selected from the group consisting of H, F, and C_{1-6} alkyl, or wherein R_5 and R_6 taken together form a substituted or unsubstituted cycloalkyl ring; wherein R_{12} is independently selected from the group consisting of substituted or unsubstituted C_{3-8} cycloalkyl, substituted or unsubstituted C_{3-8} heterocycloalkyl, 

, and 

; wherein R_7, R_8, R_9, R_{10} and R_{11} are independently selected from the group consisting of H, halogen, CN, CF_3, C_{1-6} alkyl, aryl, heteroaryl, $-O(C_{1-6}$ alkyl), -O(aryl), -O(heteroaryl), $-CO_2H$, $-CO_2(C_{1-6}$ alkyl), $-NHSO_2(C_{1-6}$ alkyl), $-NHSO_2$(aryl), -


$NHCONH(C_{1-6}$ alkyl), $-NHCON(C_{1-6}$ alkyl$)_2$, $-N(C_{1-6}$ alkyl$)CONH_2$, $-N(C_{1-6}$ alkyl$)CONH(C_{1-6}$ alkyl), $-N(C_{1-6}$ alkyl$)CON(C_{1-6}$ alkyl$)_2$, $-SO_2(C_{1-6}$ alkyl), $-SO_2NH_2$, $-SO_2NH(C_{1-6}$ alkyl), $-SO_2N(C_{1-6}$ alkyl$)_2$; and wherein R^{13} selected from the group consisting of $-O(C_{1-6}$ alkyl) and $-N(C_{1-6}$ alkyl$)_2$,

in the manufacture of a medicament for inducing aptosis in a cell comprising a myeloblast produced in acute myeloid leukemia or a lymphocyte produced in diffuse large B cell lymphoma.


2. Use of an anti-proliferative amount of a combination of:

at least one therapeutic agent selected from the group consisting of a bromodomain, an extra-terminal protein inhibitor, an anti-CD20 monoclonal antibody, and a BCL2 inhibitor; and


a compound having a structure of Formula (I):



(I)

or a stereoisomer, a pharmaceutically acceptable salt, or solvate thereof, wherein R_1, R_2, R_3, and R_4 are independently selected from the group consisting of H, Cl, -CN and $-CF_3$; wherein A is selected from the group consisting of H and C_{1-6} alkyl; wherein D is selected from the group consisting of -OH and $-O(C_{1-6}$ alkyl); wherein R_5 and R_6 are independently selected from the group consisting of H, F, and C_{1-6} alkyl, or wherein R_5 and R_6 taken together form a substituted or unsubstituted cycloalkyl ring; wherein R_{12} is independently selected from the group consisting of substituted or unsubstituted C_{3-8} cycloalkyl, substituted or unsubstituted C_{3-8} heterocycloalkyl, 

, and



; wherein R_7, R_8, R_9, R_{10} and R_{11} are independently selected from the group consisting of H, halogen, CN, CF_3, C_{1-6} alkyl, aryl, heteroaryl, -O(C_{1-6} alkyl), -O(aryl), -O(heteroaryl), -CO_2H, -CO_2(C_{1-6} alkyl), -$NHSO_2$(C_{1-6} alkyl), -$NHSO_2$(aryl), -NHCONH(C_{1-6} alkyl), -NHCON(C_{1-6} alkyl)$_2$, -N(C_{1-6} alkyl)$CONH_2$, -N(C_{1-6} alkyl)CONH(C_{1-6} alkyl), -N(C_{1-6} alkyl)CON(C_{1-6} alkyl)$_2$, -SO_2(C_{1-6} alkyl), -SO_2NH_2, -SO_2NH(C_{1-6} alkyl), -SO_2N(C_{1-6} alkyl)$_2$; and wherein R^{13} selected from the group consisting of -O(C_{1-6} alkyl) and –N(C_{1-6} alkyl)$_2$,

in the manufacture of a medicament for treating acute myeloid leukemia or diffuse large B cell lymphoma in a patient in need thereof.

3. The use of any one of Claims 1-2, wherein R_9 is selected from the group consisting of H, halogen, CN, CF_3, C_{1-6} alkyl, aryl, heteroaryl, -O(aryl), -O(heteroaryl), -CO_2H, -CO_2(C_{1-6} alkyl), -$NHSO_2$(C_{1-6} alkyl), -$NHSO_2$(aryl), -NHCONH(C_{1-6} alkyl), -NHCON(C_{1-6} alkyl)$_2$, -N(C_{1-6} alkyl)$CONH_2$, -N(C_{1-6} alkyl)CONH(C_{1-6} alkyl), -N(C_{1-6} alkyl)CON(C_{1-6} alkyl)$_2$, -SO_2(C_{1-6} alkyl), -SO_2NH_2, -SO_2NH(C_{1-6} alkyl), -SO_2N(C_{1-6} alkyl)$_2$; and wherein R^{13} selected from the group consisting of -O(C_{1-6} alkyl) and –N(C_{1-6} alkyl)$_2$.

4. The use of any one of Claims 1-3, wherein the cell is mammalian.

5. The use of any one of Claims 1-4, wherein the cell is human.

6. The use of any one of Claims 1-5, wherein the cell is *in vitro*.

7. The use of any one of Claims 1-6, wherein the cell is *in vivo*.

8. The use of any one of Claims 1-7, wherein the therapeutic agent is a bromodomain and extra-terminal protein inhibitor.

9. The use of any one of Claims 1-7, wherein the bromodomain and extra-terminal protein inhibitor is OTX015.

10. The use of any one of Claims 1-7, wherein the therapeutic agent is an anti-CD20 monoclonal antibody.

11. The use of any one of Claims 1-7, wherein the anti-CD20 monoclonal antibody is rituximab.


12. The use of any one of Claims 1-7, wherein the therapeutic agent is a BCL2 inhibitor.

13. The use of any one of Claims 1-7, wherein the BCL2 inhibitor is venetoclax.

14. The use of any one of Claims 1-13, wherein R_9 is selected from the group consisting of aziridinyl, azetidinyl, pyrrolidinyl, and morpholinolyl.

15. The use of any one of Claims 1-13, wherein R_9 is selected from the group consisting of isopropyl and cyclopropyl.

16. The use of any one of Claims 1-13, wherein the compound has a structure of Formula (Ia):




(Ia)


or a stereoisomer, a pharmaceutically acceptable salt, or solvate thereof, wherein R_1, R_2, R_3, and R_4 are independently selected from the group consisting of H and Cl; wherein R_7, R_8, R_{10} and R_{11} are independently selected from the group consisting of H and halogen; and wherein R_9 is independently selected from the group consisting C_{3-8} cycloalkyl and C_{3-8} heterocycloalkyl.

17. The use of any one of Claims 1-13, wherein R_1 and R_4 are Cl and R_2 and R_3 are H.


18. The use of any one of Claims 1-13, wherein the compound has a structure selected from the group consisting of:




,


















,



,









,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,





or a stereoisomer, a pharmaceutically acceptable salt, ester, or solvate thereof.

19. The use of any one of Claims 1-13, wherein the compound has a structure selected from the group consisting of:


,

,

,

,

,

,




or a stereoisomer, a pharmaceutically acceptable salt, ester, or solvate thereof.

20. The use of any one of Claims 1-13, wherein the compound has a structure selected from the group consisting of:


,

,

,

,


or a stereoisomer, a pharmaceutically acceptable salt, ester, or solvate thereof.

21. The use of any one of Claims 1-13, wherein the compound has a structure selected from the group consisting of:


,

,

,

or a stereoisomer, a pharmaceutically acceptable salt, ester, or solvate thereof.


22. The use of any one of Claims 1-13, wherein the compound has a structure:



,

or a stereoisomer, a pharmaceutically acceptable salt, ester, or solvate thereof.


23. The use of any one of Claims 1-13, wherein the compound has a structure:



,

or a stereoisomer, a pharmaceutically acceptable salt, ester, or solvate thereof.

24. The use of any one of Claims 1-13, wherein the compound has a structure:




,

or a stereoisomer, a pharmaceutically acceptable salt, ester, or solvate thereof.



25. A pharmaceutical composition, comprising:

at least one therapeutic agent selected from the group consisting of a bromodomain, an extra-terminal protein inhibitor, an anti-CD20 monoclonal antibody, and a BCL2 inhibitor; and

a compound having a structure of Formula (I):



(I)

or a stereoisomer, a pharmaceutically acceptable salt, or solvate thereof, wherein R_1, R_2, R_3, and R_4 are independently selected from the group consisting of H, Cl, -CN and $-CF_3$; wherein A is selected from the group consisting of H and C_{1-6} alkyl; wherein D is selected from the group consisting of -OH and $-O(C_{1-6}$ alkyl); wherein R_5 and R_6 are independently selected from the group consisting of H, F, and C_{1-6} alkyl, or wherein R_5 and R_6 taken together form a substituted or unsubstituted cycloalkyl ring; wherein R_{12} is independently selected from the group consisting of substituted or unsubstituted C_{3-8} cycloalkyl, substituted or unsubstituted C_{3-8} heterocycloalkyl, , and ; wherein R_7, R_8, R_9, R_{10} and R_{11} are independently selected from the group consisting of H, halogen, CN, CF_3, C_{1-6} alkyl, aryl, heteroaryl, $-O(C_{1-6}$ alkyl), -O(aryl), -O(heteroaryl), $-CO_2H$, $-CO_2(C_{1-6}$ alkyl), $-NHSO_2(C_{1-6}$ alkyl), $-NHSO_2$(aryl), $-NHCONH(C_{1-6}$ alkyl), $-NHCON(C_{1-6}$ alkyl)$_2$, $-N(C_{1-6}$ alkyl)$CONH_2$, $-N(C_{1-6}$ alkyl)$CONH(C_{1-6}$ alkyl), $-N(C_{1-6}$ alkyl)$CON(C_{1-6}$ alkyl)$_2$, $-SO_2(C_{1-6}$ alkyl), $-SO_2NH_2$, $-SO_2NH(C_{1-6}$ alkyl), $-SO_2N(C_{1-6}$ alkyl)$_2$; and wherein R^{13} selected from the group consisting of $-O(C_{1-6}$ alkyl) and $-N(C_{1-6}$ alkyl)$_2$.